InstalabLoading...
InstalabLoading...
If you have unexplained digestive symptoms, a family history of Crohn's disease or celiac disease, or you suspect that your gut wall is letting things through that shouldn't get through, this test gives you a window into something a standard panel cannot see. It estimates how tight, or how leaky, the lining of your small intestine actually is.
You drink a small dose of two sugars, then collect urine for several hours. The result tells you how much of each sugar crossed the gut wall and reached your bloodstream. The pattern hints at whether your barrier is doing its job, or whether things are slipping through gaps that should be sealed.
The lactulose/mannitol ratio (often shortened to LMR or L:M) compares the urinary recovery of two sugars you drink. Lactulose is a large sugar that is normally only slightly absorbed, mainly squeezing between cells through tight junctions, the protein seals that hold gut lining cells together. More lactulose in your urine means more leaking between cells. Mannitol is a smaller sugar that is readily absorbed through the cell surface, so its recovery reflects how much intact absorptive surface area you have.
A higher ratio means more lactulose got through relative to mannitol. That can happen because the seals between cells are looser, because the absorptive surface is shrunken (for example, with flattened intestinal villi), or both. A lower ratio generally points to a more intact barrier with healthy absorptive surface.
Your small intestine has a single layer of cells separating roughly five meters of digestive contents from your bloodstream. When that barrier loosens, larger molecules and microbial fragments can cross more easily and prime the immune system. Researchers have linked this kind of barrier dysfunction to inflammatory, autoimmune, and metabolic conditions, though the strength of the link varies by disease.
In a study of 1,420 healthy first-degree relatives of people with Crohn's disease, those with a baseline LMR above 0.03 were about 3 times as likely to develop Crohn's disease in the years that followed. The barrier change appeared before any clinical disease, suggesting that increased permeability is part of how Crohn's gets started, not just a downstream consequence.
In people with active Crohn's disease, the test shows a clear pattern: lower mannitol (less surface area) and higher lactulose (leakier seals), with the highest ratios in flares. The signal weakens in remission, and the test is not reliable for picking up subclinical ileal disease.
In 121 individuals studied across new-onset, long-standing, and pre-clinical (autoantibody-positive) type 1 diabetes, intestinal permeability measured by the lactulose/mannitol test was increased before clinical diabetes appeared. The barrier change preceded the disease, supporting the idea that the gut plays a role in the autoimmune process that destroys insulin-producing cells.
In active celiac disease, the test reliably distinguishes patients from healthy controls. In first-degree relatives of celiac patients, an elevated ratio can flag latent disease before villous flattening shows up on biopsy. In gluten sensitivity without celiac disease, by contrast, permeability can actually be lower than in healthy controls, with increased expression of a tight-junction protein called claudin-4. The test alone is not a good screen for silent celiac disease in the general population, because most biopsy-confirmed cases in screened adolescents had normal ratios.
In a study of 76 people with diarrhea-predominant IBS, about 39% had increased intestinal permeability on the lactulose/mannitol test, and the leakier subgroup had more severe symptoms and greater visceral and thermal pain sensitivity. The test does not diagnose IBS, but it can identify a subgroup whose symptoms track with measurable barrier dysfunction.
In 44 people with chronic heart failure compared with controls, the lactulose/mannitol ratio was about 35% higher, alongside altered gut morphology and absorption. The investigators tied these gut changes to the chronic inflammation and unintentional weight loss that can come with advanced heart failure.
In a pilot study of people with relapsing-remitting multiple sclerosis, about 73% had a lactulose/mannitol ratio above 0.025, the threshold the investigators used to define abnormal permeability. The pattern suggests gut barrier disruption may be common in MS, with possible implications for how oral medications are absorbed.
In a study of people with alcoholic liver disease, the small-bowel lactulose/mannitol ratio was not different from controls. The barrier disruption appeared mainly in the colon, picked up by other sugar probes. In hospitalized patients with cirrhosis, most had a lactulose/mannitol ratio above 0.07, and higher values were tied to spontaneous bacterial peritonitis. However, in a prospective study of 62 cirrhosis patients, the test did not reliably predict overall survival or future bacterial infections.
It can be confusing that the same test points one way in celiac disease and the opposite way in non-celiac gluten sensitivity. The ratio is not a simple good number, bad number marker. It is a phenotype indicator: it tells you whether your barrier is leakier, tighter, or has less absorptive surface than usual. Different diseases produce different barrier signatures. The clinical meaning of an elevated or reduced ratio depends on the context, your symptoms, and what other tests show.
In 27 people with obesity undergoing weight reduction, those with non-alcoholic fatty liver disease had elevated lactulose/mannitol ratios at baseline that fell into the normal range as they lost weight. In 24 people on a very-low-calorie ketogenic diet for 8 weeks, the ratio rose by roughly 76%, suggesting the diet may worsen barrier function despite producing weight loss. A systematic review concluded that increased permeability is positively associated with obesity combined with metabolic syndrome, although the evidence linking these specific patterns to long-term human health outcomes remains inconclusive.
There is no single universally accepted normal range for the lactulose/mannitol ratio. Cutpoints differ by lab, by collection window, by dose, and by population, and the test mainly reflects permeability to small sugars, not larger antigens. The values below come from published research and should be treated as orientation, not as universal targets.
| Tier | Approximate Ratio | What It Suggests |
|---|---|---|
| Likely intact barrier | Below approximately 0.03 | No clear evidence of increased small-intestinal permeability in research populations |
| Borderline / research threshold | Around 0.03 | Threshold above which Crohn's disease relatives showed about 3 times the risk of later disease |
| Likely impaired barrier | Above 0.07 to 0.10 | Pattern seen in hospitalized cirrhosis, environmental enteropathy in children, and active inflammatory bowel disease |
In one controlled study of healthy adults using a 0 to 6 hour collection, ratios in the middle 50% of the group ranged from about 0.70 to 1.14, illustrating how dramatically values shift with collection window and dosing. Compare your results within the same lab over time for the most meaningful trend. A single number from one lab cannot be directly compared to a number from another lab using a different protocol.
A single lactulose/mannitol ratio is a snapshot. The test has meaningful day-to-day variability, and methodological differences between collections can shift the number even when nothing about your gut has changed. The most useful information comes from tracking your trend within the same lab using the same protocol. If you are baseline-testing for the first time, consider retesting in 3 to 6 months if you are making meaningful changes (a sustained dietary shift, a new medication, recovery from gut illness, or weight loss), and at least annually thereafter if you are using the test as part of a broader gut-health workup.
An elevated ratio on its own does not name a disease. It flags a pattern that warrants more investigation, especially if you have symptoms or a family history. Reasonable next steps include checking celiac serology (tTG-IgA with total IgA), inflammatory markers (hs-CRP, fecal calprotectin), and a comprehensive stool analysis to look at the microbiome and digestive function. If you have a first-degree relative with Crohn's disease or celiac disease, or autoantibody evidence of early type 1 diabetes risk, consider involving a gastroenterologist who can decide whether endoscopy or biopsy is appropriate. If your result is mildly elevated and you have no symptoms or family history, a confirmatory retest in 8 to 12 weeks is often the most informative next step before doing anything more invasive.
Evidence-backed interventions that affect your Lactulose/Mannitol Ratio level
Lactulose/Mannitol Ratio is best interpreted alongside these tests.